Diethylstilbestrol glutamate as a potential substrate for ADEPT

Journal of Drug Targeting

Volumn 14, Issue 6, 2006, Pages 437-443

  Pedone, Elisa ^a   Searle, Frances ^a   Brocchini, Steve ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ADEPT; CPG2; DES glutamate; Diethylstilbestrol

Indexed keywords

CARBAMIC ACID; CARBOXYPEPTIDASE G2; DIETHYLSTILBESTROL DERIVATIVE; DIETHYLSTILBESTROL GLUTAMATE; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG STRUCTURE; ENZYME BINDING; ENZYME KINETICS; ENZYME RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN HYDROLYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETHYLSTILBESTROL; GAMMA-GLUTAMYL HYDROLASE; GLUTAMATES; MOLECULAR STRUCTURE; NEOPLASMS; PRODRUGS; SOLUBILITY; SUBSTRATE SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 33746954519     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600834573     Document Type: Article

References (40)

1. Airy, SC and Sinsheimer, JE. (1981) Isomerization of trans-diethylstilbestrol to pseudodiethylstilbestrol Steroids, 38(5), pp. 593-603.
2. Ast, Ag. (2003) Drug-targeting strategies for prostate cancer Curr Pharm Des, 9, pp. 455-466.
3. Blakey, DC and Davies, DH and Dowell, RI and East, SJ and Burke, PJ and Sharma, SK and Springer, CJ and Mauger, AB and Melton, RG. (1995) Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs Br J Cancer, 72(5), pp. 1083-1088.
4. Burke, P. (1996) Alkylating agent prodrugs for ADEPT Adv Drug Deliv Rev, 22(3), pp. 331-340.
5. Chodak, GW and Keane, T and Klotz, L. (2002) The Hormone Therapy Study Group, critical evaluation of hormonal therapy for carcinoma of the prostate Urology, 60, pp. 201-208.
6. Colapinto, V and Aberhart, C. (1961) Clinical trial of massive stilbestrol diophosphate therapy in advanced carcinoma of the prostate Br J Urol, 33, pp. 171-177.
7. Degen, GH and McLachlan, JA. (1983) Non-estrogenic metabolites of diethylstilbestrol produced by prostaglandin synthase mediated metabolism Steroids, 42(3), pp. 253-265.
8. Dowell, RI and Springer, CJ and Davies, DH and Hadley, EM and Burke, PJ and Boyle, FT and Melton, RG and Connors, TA and Blakey, DC and Mauger, AB. (1996) New mustard prodrugs for antibody-directed enzyme prodrug therapy: Alternatives to the amide link J Med Chem, 39(5), pp. 1100-1105.
9. Harada, M and Kobayashi, K and Matsueda, S and Nakagawa, M and Noguchi, M and Itoh, K. (2003) Prostate specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients Prostate, 57, pp. 152-159.
10. Kalach, JJ and Joly-Pharaboz, MO and Chantepie, J and Nicolas, B and Descotes, F and Mauduit, C and Benahmed, M and Andre, J. (2005) Divergent biological effects of estradiol and diesthylstilbestrol in the prostrate cancer cell line MOP J Steroid Biochem Mol Biol, 96, pp. 119-129.
11. Khan, TH and Eno-Amooquaye, EA and Searle, F and Browne, PJ and Osborn, HMI and Burke, J. (1999) Novel inhibitors of carboxypeptidase G(2) (CPG(2)): Potential use in antibody-directed enzyme prodrug therapy J Med Chem, 42(6), pp. 951-956.
12. Koike, H and Ito, K and Takezawa, Y and Oyama, T and Yamanaka, H and Suzuki, K. (2005) Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: Implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer Br J Cancer, 92(8), pp. 1538-1544.
13. Lampe, MI and Molkenboer-Kuenen, JDM and Oosterwijk, E. (2004) Development of new prostate specific monoclonal antibodies Prostate, 58, pp. 225-231.
14. Lee, Z and Sodee, DB and Resnick, M and MacLennan, GT. (2005) Multimodal and three-dimensional imaging of prostate cancer Comput Med Imaging Graph, 29, pp. 477-486.
15. Meredith, RF and Khazaeli, MB and Marey, DJ and Grizzle, WE and Mayo, M and Schlom, J and Russell, CD and LoBuglio, AF. (1999) Phase II study of interferon-enhanced I-131 labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer Clin Cancer Res, 5(10), pp. 3254S-3258S.
16. Miyamoto, H and Messing, EM and Chang, C. (2004) Androgen deprivation therapy for prostate cancer: Current status and future prospects Prostate, 61, pp. 322-353.
17. Montgomery, RB and Bonham, M and Nelson, PS and Grim, J and Makary, K and Vessella, R and Stahl, WL. (2005) Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells Prostate, 65, pp. 141-150.
18. Muthuramalingam, SR and Patel, K and Protheroe, A. (2004) Management of patients with hormone refractory prostate cancer Clin Oncol, 16, pp. 5050-5516.
19. Niculescu-Duvaz, D and Nicuslescu-Duvaz, I and Friedlos, F and Martin, J and Sooner, R and Davies, L and Marais, R and Springer, C. (1998) Self-immolative nitrogen mustard prodrugs for suicide gene therapy J Med Chem, 41, pp. 5297-5309.
20. Niculescu-Duvaz, D and Scanlon, J and Niculescu-Duvaz, I and Springer, CJ. (2005) A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate Tetrahedron Lett, 46, pp. 6919-6922.
21. O'Donnell, RT and DeNardo, SJ and Shi, XB and Mirick, GR and DeNardo, GL and Kroger, LA and Meyers, FJ. (1998) L6 monoclonal antibody binds prostate cancer Prostate, 37, pp. 91-97.
22. Oiu, CH and Ohe, M and Koibuchi, N and Matsuzaki, S. (2004) Apoptosis in the epididymal epithelium of adult male golden hamster exposed to diethylstilbestrol J Histochem Cytochem, 52(2), pp. 187-192.
23. Robertson, CN and Roberson, KM and Padilla, GM and O'Brien, ET and Cook, JM and Kim, CS and Fine, RL. (1996) Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells J Natl Cancer Inst, 88(13), pp. 908-917.
24. Sayed, Y and Taxel, P. (2003) The use of estrogen therapy in men Curr Opin Pharmacol, 3, pp. 650-654.
25. Scherr, DS and Pitts, WR. (2003) The nonsteroidal effects of diethylstilbestrol: The rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer J Urol, 170(5), pp. 1703-1708.
26. Scherr, D and Pitts, WR and Vaughan, ED. (2002) Diethylstilbestrol revisited: Androgen deprivation, osteoporosis and prostate cancer J Urol, 167(2), pp. 535-538.
27. Senter, PD and Springer, CJ. (2001) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates Adv Drug Deliv Rev, 53, pp. 247-264.
28. Sharma, SK and Bagshawe, KD and Begent, RH. (2005) Advances in antibody-directed enzyme prodrug therapy Curr Opin Investig Drugs, 6, pp. 611-615.
29. Springer, CJ and Antoniw, P and Bagshawe, KD and Searle, F and Bisset, GMF and Jarman, M. (1990) Novel prodrugs which are activated to cytotoxic alkylating agets by carboxypeptidaseG2 J Med Chem, 33, pp. 677-681.
30. Springer, CJ and Bagshawe, KD and Sharma, SK and Searle, F and Boden, JA and Antoniw, P and Burke, PJ and Rogers, GT and Sherwood, RF and Melton, RG. (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds Eur J Cancer, 11, pp. 1362-1366.
31. Springer, CJ and Dowell, R and Burke, PJ and Hadley, E and Davies, DH and Blakey, DC and Melton, RG and Niculescu-Duvaz, I. (1995) Optimisation of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy J Med Chem, 38, pp. 5051-5065.
32. Swain, SM and Lippman, ME. (1990) Endocrine therapies of cancer. In Cancer chemotherapy: Principles and practice. (pp. 79-109). Philadelphia: JB Lipincott Co.
33. Takezawa, Y and Nakata, S and Kobayashi, M and Kosaku, N and Fukabori, Y and Yamanaka, H. (2001) Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer Scand J Urol Nephrol, 35, pp. 283-287.
34. Talwar, GP and Gupta, R and Gupta, SK and Malhotra, R and Khanna, R and Mitra, DK and Sehgal, S and Minz, R and Kumar, A. (2001) A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells Prostate, pp. 207-213.
35. Ton, GN and Fine, JP and Kwon, GS. (2005) Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting. Part I: Synthesis and characterization J Control Release, 104, pp. 129-139.
36. Tzanavaras, PD and Themelis, DG and Karlberg, B. (2002) Rapid spectrophotometric determination of fosfestrol following on-line hydrolysis by alkaline phosphatase using flow injection and chasing zones Anal Chim Acta, 462, pp. 119-124.
37. Valencic, M and van der Does, T and de Vroom, E. (1998) Titanium tetrachloride promoted hydrolysis of cephalosporin tert-butyl esters Tetrahedron Lett, 39(12), pp. 1625-1628.
38. Vallabhajosula, S and Kuji, I and Hamacher, KA and Konishi, S and Kostakoglu, L and Kothari, PA and Milowski, MI and Nanus, DM and Bander, NH and Goldsmith, SJ. (2005) Pharmacokinetics and biodistribution of In-111-Lu-177-labeled J591 antibody specific membrane antigen: Prediction of Y-90-J591 radiation dosimetry based on In-111 or Lu-177 J Nucl Med, 46(4), pp. 634-641.
39. Vogelzang, NJ. (1992) Chemotherapy of genitourinary cancer. In The chemotherapy source book. (pp. 1008-1038). Baltimore, MD: Williams & Wilkins.
40. Winkler, VW and Nyman, MA and Egan, RS. (1971) Diethylstilbestrol cis-trans isomerization and estrogen activity of diethylstilbestrol isomers Steroids, 17(2), pp. 197-207.